Introduction
============

*Streptococcus suis* is one of the most important pathogens in the swine industry causing septicemia, meningitis, septic arthritis, and pneumonia, leading to large economic losses worldwide ([@B10]; [@B13]). In addition, *S. suis* is an emerging zoonotic agent responsible for the severe systemic infections with high morbidity and mortality rates in humans, especially in people who are in close occupational contact with pigs and pork products ([@B14]). Over the past decades, the number of reported cases of *S. suis* infections has significantly increased in humans, with two large outbreaks in humans in 1998 and 2005 in China ([@B17]). More importantly, a concise solution for streptococcosis on pig farms is not available and the effective antimicrobials are still needed to control *S. suis* infections ([@B29]). In general, penicillin is used to treat and control infections due to *S. suis*. However, penicillin-resistant strains and strains highly resistant to other β-lactam antibiotics have been reported ([@B18]). Therefore, novel antibiotics or effective treatment strategies against *S. suis* infections are urgently needed.

Tulathromycin is a long acting, semi-synthetic macrolide antibiotic, developed for the treatment and control of bacterial respiratory diseases in cattle and swine ([@B7]). The list of approved indications by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) includes *Mannheimia haemolytica, Actinobacillus pleuropneumoniae*, and *Pasteurella multocida* ([@B9]). Additionally, tulathromycin is also registered for the treatment of interdigital necrobacillosis caused by *Porphyromonas levii* ([@B30]). Of note, label indications may vary between countries and may be regionally updated ([@B30]). However, tulathromycin is currently not indicated for *S. suis* infections. Given that tulathromycin has activity against a wide range of respiratory associated pathogens and other macrolides are used for treatment of *Streptococcus pneumoniae*, we wanted to further investigate its *ex vivo* activity of tulathromycin against *S. suis* infections. We especially wanted to include *S. suis* capsular serotype 2 strains because these are the most virulent and dominant pathogenic serotypes in severe infections in both swine and humans globally ([@B18]; [@B10]). Moreover, we studied the effect of varying testing matrices on susceptibility, the post-antibiotic effect (PAE) and post-antibiotic sub-MIC (minimal inhibitory concentration) effect (PA-SME) of tulathromycin against *S. suis*. This finding could provide a framework for setting the basis for new treatment strategies and for the discovery of new macrolides with further applications in veterinary and human medicine ([@B30]).

Materials and Methods {#s1}
=====================

Animals and Experimental Design
-------------------------------

Eight healthy castrated crossbred piglets (Duroc × Landrace × Yorkshire; four males, four females) weighing 20.5--23.6 kg were used for a two-period crossover study. The piglets were allowed *ad libitum* access to water and antibiotic-free food. They were maintained in accordance with National Standards for Laboratory Animals of China (GB 14925-2010). The animal experiment procedures were approved by the Animal Research Committees of South China Agricultural University. Each piglet received tulathromycin (Draxxin Pfizer Animal Health, Sandwich, Kent, United Kingdom) at a single dose of 2.5 mg/kg by intravenous (IV) and intramuscular (IM) injections.

Sampling Procedures and Analysis of Tulathromycin
-------------------------------------------------

Blood samples (5 mL volume) were collected by venipuncture of the anterior vena cava into vacutainers (Becton, Dickinson and Company, Oxford, Oxon, United Kingdom) lacking anticoagulant, and stored in the dark. All samples were centrifuged at 3000 × *g* for 10 min at 4°C, and the supernatants stored at -80°C prior to assay for drug concentration and for measurement of *ex vivo* antimicrobial activity.

All frozen serum samples were thawed at room temperature. Roxithromycin (0.20 μg/mL) was added as internal standard ([@B32]). For drug extraction, 0.5 mL sample aliquots were transferred to centrifuge tubes, and then mixed with 0.5 mL of acetonitrile. After vortexing (1 min) and centrifugation (12,000 × *g*, 10 min), the supernatant was filtered through a 0.22 μm nylon syringe filter. The drug levels in serum were determined by a liquid chromatography-tandem mass spectrometry method (Agilent 1200 HPLC system; API 4000 triple quadrupole mass spectrometer) as previously reported ([@B32]). The limit of quantification and detection were 0.01 and 0.005 μg/mL, respectively. The correlation coefficient (*R*) was above 0.999 in the linear range of 0.01--0.5 μg/mL. All serum samples that had concentrations above 0.5 μg/mL were diluted proportionally with control serum prior to extraction with acetonitrile. The recoveries of tulathromycin were \>85%, and relative standard deviations (SDs) for both interday and intraday were \<10% at all tested concentrations. In addition, the protein binding of tulathromycin was determined at spiked concentrations of 0.05, 0.5, and 5 μg/mL using ultrafiltration methods as our previously reported ([@B34]).

Pharmacokinetic Analysis
------------------------

Tulathromycin time--concentration data in serum of individual piglets were analyzed using WinNonlin non-compartmental modeling (Version 6.1, Pharsight, St. Louis, MO, United States). The maximal drug concentration (*C*~max~) was determined directly from the data with *T*~max~ defined as the time of the first occurrence of *C*~max~. The linear trapezoidal rule was used to calculate area under the concentration--time curve (AUC). Additional PK parameters such as terminal half-life (T~1/2~λ~z~), total body clearance (Cl), volume of distribution at steady state (*V*~ss~), and mean residence time (MRT) were also determined. The absolute bioavailability (*F*) of tulathromycin was calculated according to the standard equations ([@B34]): *F*% = AUC~IM~/AUC~IV~ × 100%. All PK parameters are presented as mean ± SD.

*In Vitro* Susceptibility Testing
---------------------------------

Sixteen strains of *S. suis* isolated from swine suffering septicemia and pneumonia were used in this study. Routine determinations of MIC and minimal bactericidal concentration (MBC) of tulathromycin against these isolates were conducted using a broth microdilution technique in accordance with CLSI methods ([@B4]). The standard solution of tulathromycin was prepared in 0.0015 M citrate buffer, with pH adjusted to 7.0 with 0.015 M citric acid or 0.02 M NaOH. For determination of MICs in Mueller--Hinton broth (MHB), calf serum collected commercially from animals \<2 years old was supplemented at 5% (v/v) as required. MIC was defined as the lowest drug concentration of tulathromycin that inhibited the visible bacterial growth in medium ([@B33]). MBCs in MHB and serum were determined using the spot-plate technique to obtain a 3-log~10~ reduction in bacterial count relative to the initial inoculum ([@B15]). In addition, to determine the influence of test matrix on MICs, the tulathromycin MIC for *S. suis* ATCC 43765 was further determined in MHB, 100% serum and varying proportions of serum (25, 50, and 75%) mixed with MHB. All experiments were performed three times on separate occasions to ensure reproducibility.

Antimicrobial Activities of Tulathromycin and PAEs
--------------------------------------------------

*In vitro* time--kill curves of tulathromycin against *S. suis* ATCC 43765 were established using the broth clinical method as previously described ([@B16]). Briefly, tulathromycin concentrations ranging from 0.25 to 16× MIC for *S. suis* were prepared in pre-warmed MHB. For control growth curves, MHB lacking drug was used. The bacteria were diluted in MHB to 10^6^ CFU/mL and then incubated in an orbital shaking incubator at 37°C for 24 h. Aliquots of 50 μL of each culture were sampled and the viable counts (CFU/mL) were determined by 10-fold serial dilutions and spot-plate counts after incubation for 0, 3, 6, 9, and 12 h. The lowest detectable count was 40 CFU/mL. Each concentration was performed in triplicate to ensure reproducibility.

*Ex vivo* killing curves were determined as per above using the serum samples obtained from piglets at all time points from 0 to 360 h after IM dosing with an initial inoculum of 10^6^ CFU/mL of *S. suis*. Serum sample were pre-filtered through a 0.22 μm membrane to clear any possible bacterial contamination ([@B33]).

In addition, the PAEs and PA-SMEs of tulathromycin were performed by a combination of spectrophotometric method and viable count method as our previously reported ([@B33]). The optical density was converted into the amount of organisms based upon the preliminary standard curve (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). The PAE and PA-SME were calculated as follows ([@B23]; [@B33]): PAE = *T* -*C*; PA-SME = *T*~PA~ -*C*, where *T* and *T*~PA~ is the time required for viable counts of bacteria to increase by 1-log~10~ CFU in drug removal phase and sub-MIC-treated phase, respectively; *C* is the time for untreated control.

PK/PD Modeling and Data Analysis
--------------------------------

Based on *in vitro* MIC data and *in vivo* PK parameters, surrogate markers of antibacterial efficacy; i.e., the ACU~12h~/MIC over 12 h, was calculated for each tulathromycin concentration using the *ex vivo* killing curves. PK/PD modeling was used to describe the relationship between *ex vivo* AUC~12h~/MIC in serum and the antimicrobial effect measured as changes in log~10~ CFU after 12 h incubation. This model was established using the sigmoid *E*~max~ model that derived from the Hill equation ([@B26]; [@B33]): *E* = *E*~0~ + (*E*~max~ -*E*~0~) × *C*~e~*^N^*/(EC~50~*^N^* + *C*~e~*^N^*), where *E*~0~ is the log~10~ change in visible counts of drug-free control, *E*~max~ is the maximal antibacterial effect, EC~50~ is the PK/PD index target producing a 50% of maximal effect, *C*~e~ is the PK/PD index (AUC~12h~/MIC), and *N* is the Hill coefficient that represented the slope of dose--response curve. All data were analyzed using the non-linear WinNonlin regression program (Version 6.1, Pharsight). The coefficients of determination (*R*^2^) were used to estimate the variance associated with regression modeling with the PK/PD index. In addition, AUC~12h~/MIC targets corresponding to the net bacterial stasis, 1-log~10~ and 2-log~10~ reductions in bacterial counts after 12 h incubation were calculated by the *E*~max~ model for *S. suis* infection in serum.

Dose Regimen Prediction
-----------------------

Although tulathromycin is currently not indicated for *S. suis* infections, the approved dose regimen (2.5 mg/kg) for *M. haemolytica* and *P. multocida* seems not to be adequate to cover the overall MIC variabilities. In order to deduce a more rational dose regimen potentially for the treatment of *S. suis* infections, a 10,000-subject Monte Carlo simulation (Oracle Crystal Ball; Oracle Corporation, Redwood Shores, CA, United States) was employed to predict the dose distributions as follows ([@B25], [@B27]):
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Where the dose regimen is the given amount to produce a specific antibacterial activity over 5 days; Cl is the body clearance (L/kg/5 day); SF is a scaling factor, obtained by dividing the PK/PD index target, in this case, AUC~12h~/MIC, by 12 h, resulting in a SF of 0.8 for a bacteriostatic activity. *F* is the bioavailability, and *fu* is the free drug fraction.

The MIC distribution was obtained from our own laboratory in combination with data from some previous studies ([@B8]; [@B24]). In general, only susceptible *S. sui*s would be successfully treated with tulathromycin and should therefore be considered to calculate a potential dose regimen. Owing to no CLSI breakpoint available for tulathromycin against *S. suis*, we selected all the MICs equal to or less than 64 μg/mL, which was the recently reported MIC~90~ value of tulathromycin for *S. suis* isolated from pigs in the United States and Canada 2011--2015 ([@B24]).

Results
=======

Pharmacokinetics of Tulathromycin in Piglets
--------------------------------------------

After a single IM dosing, the peak concentration (*C*~max~) of tulathromycin (0.82 ± 0.25 μg/mL) was reached at 0.23 ± 0.14 h. The drug concentrations of tulathromycin in serum exceeded 0.10 μg/mL up to 48 h and were still detectable (mean; 0.01 μg/mL) at 360 h (**Figure [1](#F1){ref-type="fig"}**). The IM bioavailability of tulathromycin was 78.3 ± 19.2%, and the serum terminal half-life (*T*~1/2~λ~z~) and MRT after IV dosing (2.5 mg/kg) were 69.4 and 89.3 h, respectively. These were fairly long and resulted from both a large volume of distribution (*V*~ss~; 11.3 L/kg) and a low body clearance (Cl; 115 mL/kg/h) (**Table [1](#T1){ref-type="table"}**).

![The time--concentration profiles of tulathromycin in porcine serum following a single IV or IM administration of 2.5 mg/kg (*n* = 8).](fphar-08-00684-g001){#F1}

###### 

Pharmacokinetic parameters of tulathromycin in porcine serum after single intravenous (IV) and intramuscular (IM) administrations at 2.5 mg/kg.^a^

  Parameter^b^    Unit      IV dosing     IM dosing
  --------------- --------- ------------- -------------
  *T*~max~        h         0.08 ± 0.01   0.23 ± 0.14
  *C*~max~        μg/mL     4.78 ± 0.54   0.82 ± 0.25
  λ~z~            1/h       0.01 ± 0.01   0.01 ± 0.01
  *T*~1/2~λ~z~    h         69.4 ± 5.71   74.1 ± 10.6
  AUC~last~       μg⋅h/mL   21.8 ± 3.54   19.1 ± 4.18
  AUC~infinity~   μg⋅h/mL   22.5 ± 3.79   20.9 ± 4.46
  Cl              mL/kg/h   115 ± 19.6    --
  Cl/*F*          mL/kg/h   --            126 ± 11.5
  *V*~ss~         L/kg      11.3 ± 2.72   --
  MRT             h         89.3 ± 10.9   97.6 ± 11.3
  *F*             \%        --            78.3 ± 19.2

a

Values are means ± standard deviation (SD); (
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The protein binding of tulathromycin in porcine serum ranged from 32.3 to 39.1% at spiked levels of 0.05, 0.5, and 5 μg/mL, with a mean binding rate of 36.3%. The results indicated that the free/unbound fraction of tulathromycin in serum would be approximately 63.7%.

MICs and MBCs of Tulathromycin for *S. suis* Isolates
-----------------------------------------------------

The test matrix influenced the susceptibility of tulathromycin for *S. suis* isolates. The MIC and MBC values determined in MHB were significantly higher than those determined in porcine serum, with MHB/serum ratios of 40.3 and 11.4, respectively (**Table [2](#T2){ref-type="table"}**). The MBC/MIC ratios ranged from 2.46 to 8.75 for both test matrixes. For all the porcine *S. suis* isolates used for this study, the tulathromycin MICs in serum were in the range of 0.007--0.5 μg/mL, with MIC~50~ and MIC~90~ values of 0.06 and 0.25 μg/mL, respectively.

###### 

Tulathromycin MIC and MBC values (μg/mL) and summary of test medium effect on MICs and MBCs for *S. suis* isolates (*n* = 16).^a^

  Test matrix          MIC           MBC           MBC/MIC ratio
  -------------------- ------------- ------------- ---------------
  MHB                  2.14 (0.57)   5.28 (1.10)   2.46
  Serum                0.05 (0.04)   0.46 (0.12)   8.75
  MHB/Serum ratio^b^   40.3          11.4          --

a

The MIC and MBC values represent as geometric mean (SD) of 16

S. suis

isolates.

b

Comparison of MHB/Serum ratio differences:

P

\< 0.01.

To further compare the matrix effects, the tulathromycin MIC for *S. suis* ATCC 43765 was determined in porcine serum and in MHB supplemented to contain 25, 50, and 75% serum. The 25% serum incorporated in MHB reduced MICs more than threefold compared to that determined in 100% MHB. When increasing supplementation with serum further to 50 and 75%, an overall decrease in MIC values for *S. suis* ATCC 43765 of at least 10-folds was observed, resulting in MICs as low as 0.04--0.08 μg/mL compared to a consistent MIC of 1 μg/mL under the standard condition (**Table [3](#T3){ref-type="table"}**). A visible concentration-dependent decrease in MICs was observed with increasing proportions of serum mixed with MHB.

###### 

Tulathromycin MICs (mg/L) for *S. suis* ATCC 43765 in MHB and 25, 50, 75, and 100% porcine serum.^a,b^

  Matrix           MHB    Serum percentage in MHB^c^   Serum          
  ---------------- ------ ---------------------------- ------- ------ ------
  Geometric mean   1.00   0.31                         0.08    0.04   0.03
  SD               0.00   0.12                         0.03    0.01   0.02

a

The MIC values are the geometric mean of three independent replicates.

b

S. suis

ATCC 43765 is an reference strain of capsular serotype 2.

c

Significantly different from MIC determined in MHB (

P

\< 0.01).

Antimicrobial Activities of Tulathromycin and PAEs
--------------------------------------------------

We performed *in vitro* time--kill curves of tulathromycin in the range of 0.25--16 multiples of MIC against *S. suis.* Tulathromycin at 0.25 and 0.5× MIC produced only a slight inhibition of bacterial growth compared to control. However, persistent growth inhibition was observed when the bacteria were exposed to 1 μg/mL tulathromycin. At 2--8× MIC, the higher drug concentrations could not lead to a more rapid and greater reduction, indicating a time-dependent killing pattern for *S. suis*. Additionally, the bacterial counts were reduced by roughly 4-log~10~ CFU/mL after 9 h exposure to tulathromycin at 16× MIC (**Figure [2A](#F2){ref-type="fig"}**).

![**(A)** *In vitro* time--kill curves of tulathromycin against *S. suis* ATCC 43765 in the MHB medium (MIC~MHB~ = 1 μg/mL); **(B)** *ex vivo* inhibition of bacterial growth in porcine serum before and after IM administration of tulathromycin (MIC~serum~ = 0.031 μg/mL). Numerical values on the right for each panel are tulathromycin concentrations in serum.](fphar-08-00684-g002){#F2}

In serum collected up to 192 h, tulathromycin exerted effective growth inhibition or bactericidal effects after 12 h of incubation. However, no bactericidal activity was obtained for serum collected at 264 or 360 h, and these were followed by a 1.2-log~10~ CFU regrowth. Despite the lower MIC achieved in serum, there was a somewhat slower rate of killing in serum compared with the same multiples of MIC in MHB. Even for serum collected at 0.5 h (about 16× MIC~serum~), a reduction in bacterial counts to the detection limit was not achieved after 12 h of incubation (**Figure [2B](#F2){ref-type="fig"}**).

Removal of the tulathromycin after drug exposure for 1 h resulted in delayed regrowth (PAE) that ranged from 1.27 and 2.03 h (**Figure [3](#F3){ref-type="fig"}**). However, a longer persistent suppression of bacterial regrowth for *S. suis* was observed during the sub-MIC-treated phase (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}), with PA-SMEs of 2.47--3.10 h.

![PAE and PA-SME values (h) of tulathromycin against *S. suis* ATCC 43765. The PA-SMEs were determined after initial exposure to tulathromycin at 4× MIC. The error bars represent SD (*n* = 3).](fphar-08-00684-g003){#F3}

PK/PD Analysis and Dose Regimen Prediction
------------------------------------------

Data derived from PK/PD modeling of the *ex vivo* antibacterial activities showed a steep concentration--effect curve with the maximal bactericidal effects (*E*~max~) of 3.9-log~10~ CFU reduction in bacterial counts (**Figure [4](#F4){ref-type="fig"}**). The calculated AUC~12h~/MIC values in serum required to produce the net bacterial stasis, 1-log~10~ and 2-log~10~ killing activities were 9.62, 18.9, and 32.7, respectively (**Table [4](#T4){ref-type="table"}**).

![Plots of *ex vivo* AUC/MIC ratios versus the change of bacterial counts between 0 and 12 h (log~10~ CFU/mL) against *S. suis* ATCC 43765 in the porcine serum. The line represents the curve of predicted values based on the sigmoid *E*~max~ equation, and the points represent serum samples collected at time points from 0 to 360 h.](fphar-08-00684-g004){#F4}

###### 

PK/PD analysis of data acquired from *ex vivo* time--kill studies of tulathromycin against *S. suis* in porcine serum.

  Parameter (units)^a^                         Values
  -------------------------------------------- --------
  *E*~0~ (log CFU/mL)                          1.76
  *E*~max~ (log CFU/mL)                        -3.87
  *E*~max~ -*E*~0~ (log CFU/mL)                -5.63
      EC~50~ (h)                               17.9
      Slope (*N*)                              1.18
  AUC~12h~/MIC for static effect (h)           9.62
  AUC~12h~/MIC for 1-log~10~ kill effect (h)   18.9
  AUC~12h~/MIC for 2-log~10~ kill effect (h)   32.7

a

E

0

, difference in number of bacteria counts (log

10

CFU/mL) in drug-free sample between 0 and 12 h;

E

max

, difference in greatest amount of bacterial reduction (log

10

CFU/mL); EC

50

is the AUC/MIC value producing 50% of the maximal antibacterial effect;

N

, the slope of AUC/MIC response curve.

Tulathromycin should be administered as a single dose able to cover at least 5 days activity that required a mean Cl/*F* of 15.1 L/kg. After intramuscular dosing of tulathromycin in piglets, the *ex vivo* AUC~12h~/MIC target associated with net bacterial stasis was 9.62 h. This is equivalent to consider that a bacteriostatic activity can be obtained with a serum drug concentration equal to 0.8-folds the MIC. The distribution of tulathromycin MIC in broth matrix was transformed into vector equivalent MICs in serum by a scaling factor of 40.3 to take into account the serum effect (**Figure [5](#F5){ref-type="fig"}**). The unbound fraction is of 63.7. Accordingly, based on the results of Monte Carlo simulation, for a cumulative probability of target attainment of 90%, the predicted dose was 3.56 mg/kg (**Figure [6](#F6){ref-type="fig"}**), which was estimated to be effective to achieve a bacteriostatic activity against *S. suis* isolates over 5 days period.

![The MIC distribution for tulathromycin against *S. suis* (*n* = 441). The isolates were obtained from our own laboratory in combination with data from some previous studies ([@B8]; [@B24]). All reported MIC in broth matrix was transformed into equivalent MICs in serum by a scaling factor of 40.3 to take into account the serum effect.](fphar-08-00684-g005){#F5}

![The non-cumulative **(A)** and cumulative **(B)** distributions of tulathromycin doses for *S. suis*, as predicted by a PK/PD model for a duration of 5 days activity in terms of probability of target attainment (PTA). The vertical bar indicates the computed target dose at the cumulative PTA of 90%. Dose (0--12 mg/kg) is indicated on the *x*-axis.](fphar-08-00684-g006){#F6}

Discussion
==========

Tulathromycin is an effective veterinary-specific antibiotic for the treatment of swine and cattle respiratory diseases caused by *A. pleuropneumoniae* and *P. multocida*, with the MIC~90~ values of 16 and 2 μg/mL, respectively ([@B2]; [@B31]). Although previous studies have demonstrated the AUC/MIC ratio was the predictive PK/PD index that best correlated with the antimicrobial activity of tulathromycin ([@B9]; [@B30]), there is a paucity of pharmacodynamic studies of tulathromycin against *S. suis* to provide a comparison to the current studies. To our knowledge, this is the first study designed to evaluate the *ex vivo* antimicrobial activity and PK/PD relationships of tulathromycin against *S. suis*. In this study, tulathromycin demonstrated time-dependent bactericidal activity against *S. suis*. After a 2.5 mg/kg IM administration, tulathromycin is characterized by a rapid rate of absorption and large systemic availability, with a high absolute bioavailability of 78.3%. Of note, in general, the local inflammation caused by infections may significantly interfere with the kinetics of drug distribution and protein binding in plasma ([@B6]; [@B11]). Likewise, the prior pharmacokinetics study of tulathromycin in pigs with pulmonary inflammation revealed markedly longer elimination half-lives in plasma and in lung (126 and 165 h, respectively) ([@B11]). However, rapidly distribution and long persistence of tulathromycin in lung tissues do not indicated a direct relationship of the effective drug concentrations associated with located pathogens ([@B31]). The pharmacokinetics of free tulathromycin in pulmonary and bronchial epithelial lining fluids should be further evaluated.

The clinical efficacy of tulathromycin may be underestimated by the *in vitro* MIC measurements. Consistent with other macrolides, tulathromycin MICs measured in a biologic matrix (serum) was markedly lower than that determined in the artificial matrix (defined broth medium) ([@B1]; [@B12]). This finding is supported by a similar result from a previous study using calf serum in which the presence of 50% serum during the MIC test decreased MICs by 12-fold for *M. haemolytica* and ninefold for *P. multocida* ([@B16]). For *S. suis* isolates, our results demonstrated that incremental supplementation of culture matrix with serum resulted in noticeable shifts to lower MICs by at least 5-log~2~ dilution steps. This increased susceptibility response in porcine serum was analogous to that produced by tildipirosin, a novel macrolide, which produced progressive reductions in MICs with increasing amounts of serum for six bacterial species harvested from pigs ([@B22]). Additionally, an early antibacterial activity study in human serum demonstrated that the killing rate of erythromycin against *Escherichia coli* and *Staphylococcus aureus* was increased in the presence of serum ([@B21]).

In general, macrolides poorly diffuse across the outer membrane of most Gram-negative bacteria ([@B20]; [@B3]). The mechanism for markedly increased susceptibility of *S. suis* to tulathromycin in porcine serum is probably related to the downregulation of *opr*M and increased permeability of bacterial outer-membrane when grown in biological fluids ([@B21]; [@B3]). Consistent with this view, the previous *in vitro* susceptibility study of clarithromycin showed a considerable enhancement of antibacterial activity against *P. aeruginosa* in RPMI 1640 medium and other eukaryotic cell culture media as compared with the conventionally used broths ([@B3]). More recently, the similar negative clinical consequence was observed when testing activity of macrolide and ketolide was assessed in CA-MHB, suggesting that measuring MICs in RPMI-1640 could be easily implemented to phenotypically detect acquired resistance to macrolides in *P. aeruginosa* from cystic fibrosis patients ([@B19]). In this case, serum MIC is more predictive to provide a reasonable surrogate for studies of *in vivo* antimicrobial activity when the objective is to establish a rational dosing regimen.

Tulathromycin is the first member of a novel subclass of macrolides known as triamilides, which can be positively charged at the appropriate pH ([@B30]). The antimicrobial activity of tulathromycin may be in theory related to the matrix pH. Consistently, results from previous studies determining the effect of pH on MICs indicated greater potency of tulathromycin (lower MIC) against *M. haemolytica* and *P. multocida* as pH increased in the range of 7.0--8.2 (two extremes of pH in extracellular fluids under physiological conditions) ([@B16]). Therefore, matrix pH seems likely to be another important factor accounting for markedly augmented activity in porcine serum compared with MHB ([@B5]; [@B16]). In addition, as reported for other macrolides, tulathromycin may tend to be accumulated within lysosomes due to the relatively higher pKa (\>8.6) and acidic environment of lysosomes ([@B30]). However, given that the MICs of some pathogens are inversely related to pH, the intracellular activity of tulathromycin is probably limited ([@B28]; [@B30]).

Similar with other macrolides, tulathromycin is considered a bacteriostatic agent against *S. aureus* and *E. coli* ([@B30]). However, in this study, an *in vitro* bactericidal activity was noted at four- or eightfolds the MIC for *S. suis*. The further PK/PD-based modeling suggested that animal dose regimens should supply AUC~12h~/MIC of tulathromycin at least 9.62 to achieve a net bacteriostatic activity against *S. suis*. Based on the free drug AUC~12h~ of 5.86 μg⋅h/mL in piglets, it is apparent that the current approved dose (2.5 mg/kg) could not achieve such PD target for *S. suis* infection with a MIC~serum~ of ≥0.6 μg/mL (i.e., MIC~MHB~ of 24 μg/mL). Therefore, tulathromycin, if used for the treatment of *S. suis* infection, would benefit from larger doses than are commonly used in clinical practice.

Conclusion
==========

The present study investigated for the first time the *ex vivo* antimicrobial activities and PK/PD relationships of tulathromycin against *S. suis* in piglet serum. Based on the PK data and MIC distribution, we predicted the dosage distribution of tulathromycin, and estimated an appropriate dose (3.56 mg/kg) for a bacteriostatic activity against *S. suis* infection over 5 days period. The marked differences in MIC values between artificial media and serum highlight the importance of matrix effects on susceptibility testing. Additionally, our findings suggested that PD evaluation data for tulathromycin should be derived in biological fluids such as serum for preparing the dosage regimens for clinical therapeutic use.
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